ENPNewswire-November 7, 2011--J&J -FDA Approves XARELTO (Rivaroxaban) To Reduce The Risk Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation; XARELTO Combines Proven Effectiveness And Demonstrated Safety Profile With Convenient, Once-Daily Dosing(C)2011 ENPublishing - http://www.enpublishing.co.uk ENP Newswire - 07 November 2011